source
- Encoded Therapeutics secures $275M Series F to advance gene therapy for Dravet syndromeEncoded Therapeutics announced a $275 million Series F financing round aimed at moving its lead gene‑therapy candidate, ETX101, toward pivotal trials for Dravet syndrome. In the ongoing Phase 1/2…
- New FDA Oncology Center chief Angelo de Claro pledges AI integration and trial expansionAngelo de Claro, M.D., has taken over as the permanent head of the FDA’s Oncology Center of Excellence after serving as acting director since late 2025. In his first interview, he said the agency w…